MRNA-based HIV-1 Vaccines

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2024 Jul 17

PMID 39016564

Authors

Shamim Ahmed

Alon Herschhorn

Affiliations

Soon will be listed here.

Abstract

SUMMARYThe success of the Severe Acute Respiratory Syndrome Coronavirus 2 mRNA vaccines to lessen/prevent severe COVID-19 opened new opportunities to develop RNA vaccines to fight other infectious agents. HIV-1 is a lentivirus that integrates into the host cell genome and persists for the lifetime of infected cells. Multiple mechanisms of immune evasion have posed significant obstacles to the development of an effective HIV-1 vaccine over the last four decades since the identification of HIV-1. Recently, attempts to address some of these challenges have led to multiple studies that manufactured, optimized, and tested, in different animal models, mRNA-based HIV-1 vaccines. Several clinical trials have also been initiated or are planned to start soon. Here, we review the current strategies applied to HIV-1 mRNA vaccines, discuss different targeting approaches, summarize the latest findings, and offer insights into the challenges and future of HIV-1 mRNA vaccines.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

References

Ratnapriya S, Perez-Greene E, Schifanella L, Herschhorn A . Adjuvant-mediated enhancement of the immune response to HIV vaccines. FEBS J. 2021; 289(12):3317-3334. DOI: 10.1111/febs.15814. View

Mazurov D, Herschhorn A . Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4 T cells measures viral sensitivity to broadly neutralizing antibodies. mBio. 2023; 15(1):e0242823. PMC: 10790777. DOI: 10.1128/mbio.02428-23. View

Pardi N, Hogan M, Naradikian M, Parkhouse K, Cain D, Jones L . Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018; 215(6):1571-1588. PMC: 5987916. DOI: 10.1084/jem.20171450. View

Burton D, Mascola J . Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015; 16(6):571-6. PMC: 4834917. DOI: 10.1038/ni.3158. View

Misra M, Jeffy J, Liao C, Pickthorn S, Wagh K, Herschhorn A . HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies. Bioinformatics. 2024; 40(3). PMC: 10919947. DOI: 10.1093/bioinformatics/btae103. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Jardine J, Kulp D, Havenar-Daughton C, Sarkar A, Briney B, Sok D . HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016; 351(6280):1458-63. PMC: 4872700. DOI: 10.1126/science.aad9195. View

Herschhorn A, Haase A . Science at Its Best in the Time of the COVID-19 Pandemic. ACS Infect Dis. 2021; 7(8):2209-2210. DOI: 10.1021/acsinfecdis.1c00269. View

Garcia-Blanco M, Cullen B . Molecular basis of latency in pathogenic human viruses. Science. 1991; 254(5033):815-20. DOI: 10.1126/science.1658933. View

10.

Lewis G, DeVico A, Gallo R . Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A. 2014; 111(44):15614-21. PMC: 4226080. DOI: 10.1073/pnas.1413550111. View

11.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

12.

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

13.

Gomez C, Perdiguero B, Usero L, Marcos-Villar L, Miralles L, Leal L . Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen. Vaccines (Basel). 2021; 9(9). PMC: 8473054. DOI: 10.3390/vaccines9090959. View

14.

Smerdou C, Liljestrom P . Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther. 2001; 1(2):244-51. View

15.

Corey L, B Gilbert P, Tomaras G, Haynes B, Pantaleo G, Fauci A . Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7(310):310rv7. PMC: 4751141. DOI: 10.1126/scitranslmed.aac7732. View

16.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

17.

Chertova E, Bess Jr J, Crise B, Sowder II R, Schaden T, Hilburn J . Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 2002; 76(11):5315-25. PMC: 137021. DOI: 10.1128/jvi.76.11.5315-5325.2002. View

18.

Escolano A, Gristick H, Gautam R, DeLaitsch A, Abernathy M, Yang Z . Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Sci Transl Med. 2021; 13(621):eabk1533. PMC: 8932345. DOI: 10.1126/scitranslmed.abk1533. View

19.

Wykes M, Pombo A, Jenkins C, MacPherson G . Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol. 1998; 161(3):1313-9. View

20.

Ballesteros-Briones M, Silva-Pilipich N, Herrador-Canete G, Vanrell L, Smerdou C . A new generation of vaccines based on alphavirus self-amplifying RNA. Curr Opin Virol. 2020; 44:145-153. PMC: 7474593. DOI: 10.1016/j.coviro.2020.08.003. View